A Case of Eosinophilic Pneumonia in a Patient Receiving Dupilumab Therapy

DOI
  • Nishida Kohei
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company
  • Nagai Takaaki
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company
  • Toda Shiori
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company
  • Inazu Satsuki
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company
  • Takagi Yasuhiro
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company
  • Tamagaki Gakuya
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company
  • Fujii Tatsuo
    Department of Respiratory Medicine, Osaka General Hospital of West Japan Railway Company

Bibliographic Information

Other Title
  • デュピルマブ投与中に好酸球性肺炎を発症した1例

Search this article

Abstract

<p>Background. Dupilumab is a humanized monoclonal antibody that inhibits the interleukin-4 receptor alpha chain. It is widely used to treat atopic dermatitis, bronchial asthma, and chronic sinusitis with nasal polyps. Case. A 72-year-old woman presented to our hospital with cough, dyspnea, and loss of appetite that had persisted for approximately 7 months after commencing dupilumab therapy for chronic sinusitis with nasal polyps. Antibiotics therapy for bacterial pneumonia was initiated since she had an inflammatory response and consolidation was observed in the lung field on chest computed tomography; however, the antibiotics were ineffective. The eosinophil ratio in the bronchoalveolar lavage fluid was 76%; hence, she was diagnosed with eosinophilic pneumonia. Dupilumab was considered to have triggered the onset of eosinophilic pneumonia. Her symptoms improved following the discontinuation of dupilumab and the initiation of steroid therapy. Conclusion. It is necessary to pay attention to the underlying disease condition and the possible onset of eosinophilic pneumonia during dupilumab therapy.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top